Literature DB >> 32372331

The clinical importance of early acute hepatic porphyria diagnosis: a national cohort.

Yonatan Edel1,2,3, Rivka Mamet4, Sharon Cohen4, Daniel Shepshelovich5,6, Assi Levi7,6, Iftach Sagy8,9.   

Abstract

Acute hepatic porphyria (AHP) attacks begin with abdominal pain and can progress to severe life-threatening conditions. Early diagnosis and treatment may prevent these complications. We investigated the difference between the severity of porphyria attacks before and after porphyria diagnosis. A retrospective study including AHP patients hospitalized for an acute attack in Israel during a 15-year period. Diagnosis of an attack was based on typical clinical symptoms accompanied by at least one documented elevated urinary porphobilinogen above fourfold of normal values. The primary outcome was intensive care unit (ICU) admissions. Secondary outcomes included the length of hospital stay, severe hyponatremia, seizures, and psychiatric symptoms. 42 attacks in 9 patients were included. Most attacks occurred in women (78.6%) and in acute intermittent porphyria patients (76.2%). The mean age of attack was 26.5 (± 6.3) years. Attacks following porphyria diagnosis had a lower prevalence of ICU admission (3.3% versus 75.0%, p < 0.001), seizures (0% versus 50.0%, p < 0.001), psychiatric symptoms (23.3% versus 66.7%, p = 0.01), severe hyponatremia (16.7% versus 83.3%, p < 0.001), and median length of hospital stay (5 versus 11.0 days, p < 0.001). These results remained significant after simple univariate logistic regression for ICU admission [odds ratio (OR) 0.01, 95% confidence interval (CI) 0.00-0.12], prolonged hospital stay (OR 0.08, 95% CI 0.01-0.41), seizures or neurological symptoms (OR 0.06, 95% CI 0.01-0.30), and severe hyponatremia (OR 0.02, 95% CI 0.00-0.20). Previously diagnosed AHP patients have a significantly milder attack course as compared to previously undiagnosed patients. Family screening following sentinel cases might prevent severe AHP attacks.

Entities:  

Keywords:  Diagnosis; Intensive care; Porphobilinogen; Porphyria

Mesh:

Substances:

Year:  2020        PMID: 32372331     DOI: 10.1007/s11739-020-02359-3

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  3 in total

Review 1.  Neurological manifestations of acute intermittent porphyria.

Authors:  E Pischik; R Kauppinen
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  2009-02-16       Impact factor: 1.770

2.  EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks.

Authors:  Laurent Gouya; Paolo Ventura; Manisha Balwani; D Montgomery Bissell; David C Rees; Ulrich Stölzel; John D Phillips; Raili Kauppinen; Janneke G Langendonk; Robert J Desnick; Jean-Charles Deybach; Herbert L Bonkovsky; Charles Parker; Hetanshi Naik; Michael Badminton; Penelope E Stein; Elisabeth Minder; Jerzy Windyga; Radan Bruha; Maria Domenica Cappellini; Eliane Sardh; Pauline Harper; Sverre Sandberg; Aasne K Aarsand; Janice Andersen; Félix Alegre; Aneta Ivanova; Neila Talbi; Amy Chan; William Querbes; John Ko; Craig Penz; Shangbin Liu; Tim Lin; Amy Simon; Karl E Anderson
Journal:  Hepatology       Date:  2019-11-07       Impact factor: 17.425

3.  Porphyria: What Is It and Who Should Be Evaluated?

Authors:  Yonatan Edel; Rivka Mamet
Journal:  Rambam Maimonides Med J       Date:  2018-04-19
  3 in total
  1 in total

1.  Red urine and a red herring - diagnosing rare diseases in the light of the COVID-19 pandemic.

Authors:  Philipp Jud; Gerald Hackl; Alexander Christian Reisinger; Angela Horvath; Philipp Eller; Vanessa Stadlbauer
Journal:  Z Gastroenterol       Date:  2021-11-12       Impact factor: 1.769

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.